• 449: GLP-1 Medications: A Breakthrough for Alcoholism and Sobriety?

  • Nov 22 2024
  • Durée : 33 min
  • Podcast

449: GLP-1 Medications: A Breakthrough for Alcoholism and Sobriety?

  • Résumé

  • Join our FREE FB Support group!: https://www.facebook.com/groups/realrecoverytalk

    Download our free guides!: https://www.realrecoverytalk.com/guides

    Chat with us! https://www.realrecoverytalk.com/services

    In this episode, we take a closer look at GLP-1 medications like tirzepatide, Ozempic, and Mounjaro and their potential impact on alcoholism. These medications, widely known for treating diabetes and aiding in weight loss, are now being studied for their ability to reduce alcohol cravings and consumption. Could this be a game-changer in addiction treatment? Dr. Tamanini joins us to break down the science behind this exciting research and explain how these medications work in the body.

    We also dive into some important questions raised in our Facebook community, The Sobriety Network. How do you navigate pricing out treatment for a loved one who needs help? And is it possible to get addicted to prescription drugs while trying to stay sober? These are critical issues many in recovery face, and we offer practical advice and insights to guide you.

    If you’re curious about cutting-edge advancements in addiction science or looking for answers to common recovery challenges, this episode has something for you. Tune in to learn, grow, and stay inspired on your sobriety journey!

    Afficher plus Afficher moins
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

    Ce que les auditeurs disent de 449: GLP-1 Medications: A Breakthrough for Alcoholism and Sobriety?

    Moyenne des évaluations utilisateurs. Seuls les utilisateurs ayant écouté le titre peuvent laisser une évaluation.

    Commentaires - Veuillez sélectionner les onglets ci-dessous pour changer la provenance des commentaires.

    Il n'y a pas encore de critique disponible pour ce titre.